Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-052873
Filing Date
2025-04-10
Accepted
2025-04-10 16:30:16
Documents
20
Period of Report
2025-05-21

Document Format Files

Seq Description Document Type Size
1 DEF 14A evok-20250409.htm   iXBRL DEF 14A 911337
2 GRAPHIC img217104142_0.jpg GRAPHIC 17621
3 GRAPHIC img217104142_1.jpg GRAPHIC 17621
4 GRAPHIC img217104142_2.jpg GRAPHIC 412968
5 GRAPHIC img217104142_3.jpg GRAPHIC 401443
6 GRAPHIC img217104142_4.jpg GRAPHIC 1211325
7 GRAPHIC img217104142_5.jpg GRAPHIC 744223
  Complete submission text file 0000950170-25-052873.txt   9492372

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20250409.xsd EX-101.SCH 36734
22 EXTRACTED XBRL INSTANCE DOCUMENT evok-20250409_htm.xml XML 559635
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36075 | Film No.: 25828774
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)